November 19, 2011 -- In an exclusive ChinaBio® Today interview, Carl Firth, CEO of ASLAN Pharma, explains the company’s highly focused drug development business plan, which has in-licensed two molecules so far with a third on the way; Tiantan Biological Products has received $24 million from the Gates Foundation to develop polio vaccines; BGI partnered with the Children’s Hospital of Philadelphia to seek genetic causes of pediatric diseases; Lepu Medical Technology spent $6.6 million for a 70% share in Dutch medical device maker Comed; Pfizer’s timeline for building its Shanghai Anti-Infectives Research Unit has been extended; Novartis will invest $25 million to expand its generic drug facility in Zhongshan; Hutchison MediPharma began a Phase I clinical trial of its third cancer molecule to enter human testing; and the SFDA will begin inspecting foreign drug makers whose products are imported into China. More details….
Stock Symbols: (SHA: 600161) (SHE: 300003) (NYSE: PFE) (NYSE: NVS)
